We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Discovery and Manufacturing Strategies for Novel, Homogeneous ADC Molecules

Video   Dec 23, 2016

 

Several key learnings have emerged through application of rapid re-iterative ADC design using reactive non-natural amino acids to specifically position conjugation sites: Site-specific homogeneous molecules can improve therapeutic index preclinically and have the potential to optimize clinical impact for a given combination of antibody and warhead. Site matters. Homogeneity is required, but not sufficient, for best in class molecules. Finding the optimal site for conjugation is crucial. Beyond antibody stability, PK and attributes that optimize for internalization and cell killing in vitro, certain conjugation sites on the antibody further enhance solid tumor killing efficacy in vivo. The antibody production process has been split into two stages; First the production of the ribosome-rich extract that can now be considered a critical raw material. And secondly, use of that cell-free extract to produce nnAA containing antibodies in 10 hours from DNA. Each stage has been optimized for speed, efficiency and flexibility and now established as a viable manufacturing process: Removal of RF-1 from the extract permits very efficient production of nnAA containing Use of novel nnAAs allows complete conjugation in minutes Extracts that incorporate orthogonal tRNAs and lack RF-1 provide for efficient and flexible manufacturing.

 
 
 
 

Recommended Videos

Biohacking Your Cells to Fight Cancer

Video

This video dives into the science of how biologists are biohacking the human body to try to fix the seemingly unfixable.

WATCH NOW

How Does Flow Cytometry Work?

Video

Watch this animation to learn about the components and capabilities of flow cytometry.

WATCH NOW

The Promise and Limits of Cancer Immunotherapy

Video

A pioneer in cancer care treatment, oncologist Lennie Sender has a deep understanding of both the possibilities and limitations of harnessing the immune system to treat different types of cancer.

WATCH NOW

 

Like what you just watched? You can find similar content on the communities below.

Biopharma Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE